PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30210625-11 2018 In colon cancer PDCs with NCOA4-RET fusion, vandetanib potently inhibited AKT and ERK phosphorylation. vandetanib 44-54 AKT serine/threonine kinase 1 Homo sapiens 74-77 24256343-8 2014 The MAPK and AKT pathways were the two major signaling pathways inhibited by vandetanib. vandetanib 77-87 AKT serine/threonine kinase 1 Homo sapiens 13-16 29517106-4 2018 Furthermore, vandetanib inhibited EGFR, AKT and ERK1/2 phosphorylation and downregulated cyclin D1 in ATC cells. vandetanib 13-23 AKT serine/threonine kinase 1 Homo sapiens 40-43 28842826-10 2018 Vandetanib produces a significant decrease in vascular and neuronal densities and reduction in the expression of molecules involved in survival and proliferation processes such as phospho-Akt/Akt and phospho-Erk/Erk. vandetanib 0-10 AKT serine/threonine kinase 1 Homo sapiens 188-191 28842826-10 2018 Vandetanib produces a significant decrease in vascular and neuronal densities and reduction in the expression of molecules involved in survival and proliferation processes such as phospho-Akt/Akt and phospho-Erk/Erk. vandetanib 0-10 AKT serine/threonine kinase 1 Homo sapiens 192-195 26050198-3 2015 The data demonstrated that ZD6474 inhibited the growth of osteosarcoma cells, and promoted G1-phase cell cycle arrest and apoptosis by inhibiting the activity of EGFR tyrosine kinase, and consequently suppressing its downstream PI3k/Akt and MAPK/ERK pathway. vandetanib 27-33 AKT serine/threonine kinase 1 Homo sapiens 233-236 24526731-6 2014 Vandetanib significantly repressed tumorigenesis of MCF-7 xenografts (P < 0.001), which displayed decreased activation of ERK1/2 and AKT. vandetanib 0-10 AKT serine/threonine kinase 1 Homo sapiens 136-139 29787277-7 2018 We employ dual drugs, ZD6474, and epigallocatechin gallate (EGCG) that inhibit EGFR2, VEGFR2, and Akt signaling pathways since changes in these signaling pathways confer tamoxifen resistance in MCF 7 and T-47D cells. vandetanib 22-28 AKT serine/threonine kinase 1 Homo sapiens 98-101 24256343-13 2014 MAPK and AKT were identified as the main pathways involved in vandetanib response in MTC models. vandetanib 62-72 AKT serine/threonine kinase 1 Homo sapiens 9-12 23822199-8 2013 MAPK and AKT pathways were the two major signaling pathways inhibited by vandetanib. vandetanib 73-83 AKT serine/threonine kinase 1 Homo sapiens 9-12 23799852-7 2013 RESULTS: ZD6474-induced autophagy was dependent on signalling through the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. vandetanib 9-15 AKT serine/threonine kinase 1 Homo sapiens 100-103 23799852-7 2013 RESULTS: ZD6474-induced autophagy was dependent on signalling through the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. vandetanib 9-15 AKT serine/threonine kinase 1 Homo sapiens 140-143 23822199-12 2013 MAPK and AKT were identified as the main pathways involved in vandetanib response in MTC models. vandetanib 62-72 AKT serine/threonine kinase 1 Homo sapiens 9-12 23578175-10 2013 Moreover, treatment with RET-inhibitors, including vandetanib, reduced cell viability, which was accompanied by the downregulation of the AKT and ERK1/2 signaling pathways. vandetanib 51-61 AKT serine/threonine kinase 1 Homo sapiens 138-141 21970874-6 2011 Vandetanib significantly downregulated epidermal growth factor receptor (EGFR)/Erk/Akt phosphorylation as well as E2F-1 mRNA and TS mRNA/protein levels. vandetanib 0-10 AKT serine/threonine kinase 1 Homo sapiens 83-86 17308046-7 2007 In vitro, ZD6474 inhibited EGFR, VEGFR2, mitogen-activated protein kinase and Akt phosphorylation, EGF- and VEGF-induced proliferation, and endothelial cell tube formation and also induced apoptosis. vandetanib 10-16 AKT serine/threonine kinase 1 Homo sapiens 78-81 20139705-0 2010 ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. vandetanib 0-6 AKT serine/threonine kinase 1 Homo sapiens 84-87 18694994-4 2008 RESULTS: Multitargeted inhibitor vandetanib (ZD6474) inhibited the growth and the phosphorylation of Akt and its effector p70S6 kinase in both wild-type and EGFR inhibitor-resistant human colon, prostate, and breast cancer cells. vandetanib 33-43 AKT serine/threonine kinase 1 Homo sapiens 101-104 18694994-4 2008 RESULTS: Multitargeted inhibitor vandetanib (ZD6474) inhibited the growth and the phosphorylation of Akt and its effector p70S6 kinase in both wild-type and EGFR inhibitor-resistant human colon, prostate, and breast cancer cells. vandetanib 45-51 AKT serine/threonine kinase 1 Homo sapiens 101-104 21479415-6 2008 Western blot analysis revealed that the autophosphorylation of EGFR and Akt was increasingly decreased with ZD6474 treatment in lung and brain endothelial cells and the MDA-MB-435 cell line. vandetanib 108-114 AKT serine/threonine kinase 1 Homo sapiens 72-75 21350000-8 2011 All vandetanib-containing treatments inhibited EGFR and Akt phosphorylation in vitro and in vivo. vandetanib 4-14 AKT serine/threonine kinase 1 Homo sapiens 56-59 20139705-6 2010 ZD6474 inhibited cell proliferation in a dose-dependent manner, by blocking cell progression at the G(0)-G(1) stage, through downregulation of expression of cyclin D1 and cyclin E. In vitro, ZD6474 inhibited growth factor-induced phosphorylation of EGFR, VEGFR-2, MAPK and Akt. vandetanib 0-6 AKT serine/threonine kinase 1 Homo sapiens 273-276 19622715-0 2009 Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. vandetanib 68-78 AKT serine/threonine kinase 1 Homo sapiens 51-54 19622715-8 2009 Our results indicate that inhibition of histone deacetylation enhances the antiproliferative effect of vandetanib in malignant human glioma cell lines by enhancing inhibition of MAPK, Akt, and other downstream effectors that may have application in combinatorial therapeutics for these tumors. vandetanib 103-113 AKT serine/threonine kinase 1 Homo sapiens 184-187 19318229-5 2009 ZD6474 and ZD1839 inhibited EGF-induced phosphorylation of EGFR, AKT and ERK, whereas VEGF-induced phosphorylation of VEGFR2 was completely inhibited with 0.1 microM SU11248. vandetanib 0-6 AKT serine/threonine kinase 1 Homo sapiens 65-68 16995874-3 2006 ZD6474 induced growth arrest and apoptosis of GIST-T1 cells in association with blockade of c-Kit and its downstream effectors, including Akt and extracellular signal-regulated kinase (ERK). vandetanib 0-6 AKT serine/threonine kinase 1 Homo sapiens 138-141 16995874-4 2006 ZD6474 treatment also blocked the mammalian target of rapamycin (mTOR), which lies downstream of Akt and ERK. vandetanib 0-6 AKT serine/threonine kinase 1 Homo sapiens 97-100 17145834-6 2006 Moreover, ZD6474 inhibited phosphorylation of EGFR and Akt and triggered cell apoptosis. vandetanib 10-16 AKT serine/threonine kinase 1 Homo sapiens 55-58